{"DataElement":{"publicId":"2957357","version":"2","preferredName":"Breast Carcinoma Progesterone Receptor Status","preferredDefinition":"Text term to represent the overall result of Progresterone Receptor (PR) testing.","longName":"2534236v1.0:2957355v2.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2534236","version":"1","preferredName":"Breast Carcinoma Tumor Marker Progesterone Receptor Status","preferredDefinition":"(brest KAN-ser) Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare.:A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis_Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","longName":"2534174v1.0:2534138v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2534174","version":"1","preferredName":"Breast Carcinoma Tumor Marker","preferredDefinition":"(brest KAN-ser) Cancer that forms in tissues of the breast, usually the ducts (tubes that carry milk to the nipple) and lobules (glands that make milk). It occurs in both men and women, although male breast cancer is rare.:A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis","longName":"C4872:C17220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Tumor Marker","conceptCode":"C17220","definition":"A substance present in or produced by a tumor or by the host, that can be used for differentiating neoplastic from normal tissue based on measurements in body fluids, secretions, cells, and/or tissues. Markers are used in diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and screening in general populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"21203B8F-6157-3E6C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2534138","version":"1","preferredName":"Progesterone Receptor Status","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","longName":"C16149","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status","conceptCode":"C16149","definition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"21203005-5573-363C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"212047A9-5D92-47CB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-31","endDate":null,"createdBy":"UMLLOADER_CAE","dateCreated":"2006-10-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Permission to Release DEC granted by primary curator in 8/2008.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2957355","version":"2","preferredName":"Receptor Status","preferredDefinition":"A receptor is a protein located on the cell surface, or in the cytoplasm, that binds to a specific signaling factor, such as a hormone, antigen, or neurotransmitter, causing a conformational and functional change in the receptor molecule.  The ligand-bound receptor then alters its interaction with target molecules, which leads to changes in cellular physiology through modification of the activity of one or more signal transduction pathways._A condition or state at a particular time.","longName":"RCPT_STAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Indeterminate","valueDescription":"Indeterminate","ValueMeaning":{"publicId":"2577194","version":"1","preferredName":"Indeterminate","longName":"2577194","preferredDefinition":"Cannot distinguish between two or more possible values in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate","conceptCode":"C48658","definition":"Cannot distinguish between two or more possible values in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA97-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"COOPERM","dateModified":"2008-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A894-19B5-E040-BB89AD431EE7","beginDate":"2009-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Positive","valueDescription":"Positive Finding","ValueMeaning":{"publicId":"2931646","version":"1","preferredName":"Positive Finding","longName":"2931646","preferredDefinition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7093A8D5-881C-C40D-E040-BB89AD437437","latestVersionIndicator":"Yes","beginDate":"2009-08-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-08-07","modifiedBy":"COLBERTM","dateModified":"2022-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A89E-19B5-E040-BB89AD431EE7","beginDate":"2009-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Negative","valueDescription":"Negative Finding","ValueMeaning":{"publicId":"2617835","version":"1","preferredName":"Negative Finding","longName":"2617835","preferredDefinition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negative Finding","conceptCode":"C38757","definition":"A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CAF63D8-1F72-70DF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2007-03-27","modifiedBy":"DWARZEL","dateModified":"2022-10-03","changeDescription":"Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A8A8-19B5-E040-BB89AD431EE7","beginDate":"2009-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A8B2-19B5-E040-BB89AD431EE7","beginDate":"2010-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Borderline","valueDescription":"Borderline Receptor Result","ValueMeaning":{"publicId":"3010632","version":"1","preferredName":"Borderline Receptor Result","longName":"3010632","preferredDefinition":"Straddling the dividing line between two categories.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Borderline","conceptCode":"C14157","definition":"Straddling the dividing line between two categories.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FBD0CB7-1F11-961E-E040-BB89AD43429C","latestVersionIndicator":"Yes","beginDate":"2010-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A8BC-19B5-E040-BB89AD431EE7","beginDate":"2010-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Not Performed","valueDescription":"Not Performed","ValueMeaning":{"publicId":"3027962","version":"1","preferredName":"Not Performed","longName":"3027962","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8212C367-45D9-76C9-E040-BB89AD435F6E","latestVersionIndicator":"Yes","beginDate":"2010-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A8C6-19B5-E040-BB89AD431EE7","beginDate":"2010-05-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Performed but Not Available","valueDescription":"Performed but Not Available","ValueMeaning":{"publicId":"3104250","version":"1","preferredName":"Performed but Not Available","longName":"3104250","preferredDefinition":"Performed; carried out.: An operation in which a term denies or inverts the meaning of another term or construction.: Available; obtainable or accessible and ready for use or service.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Availability","conceptCode":"C25429","definition":"The quality of being obtainable or accessible and ready for use or service.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F8B670-A8D6-19B5-E040-BB89AD431EE7","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"87F8B670-A8EF-19B5-E040-BB89AD431EE7","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","deletedIndicator":"No"},{"value":"Equivocal","valueDescription":"Equivocal","ValueMeaning":{"publicId":"3128156","version":"1","preferredName":"Equivocal","longName":"3128156","preferredDefinition":"Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Equivocal","conceptCode":"C86071","definition":"Open to question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8DA5AC48-79E6-E2FD-E040-BB89AD4306E2","latestVersionIndicator":"Yes","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8DA5AC48-79FF-E2FD-E040-BB89AD4306E2","beginDate":"2010-08-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-08-12","modifiedBy":"ONEDATA","dateModified":"2010-08-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2957354","version":"1","preferredName":"Receptor Status","preferredDefinition":"A receptor is a protein located on the cell surface, or in the cytoplasm, that binds to a specific signaling factor, such as a hormone, antigen, or neurotransmitter, causing a conformational and functional change in the receptor molecule.  The ligand-bound receptor then alters its interaction with target molecules, which leads to changes in cellular physiology through modification of the activity of one or more signal transduction pathways.:A condition or state at a particular time.","longName":"C18106:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receptor","conceptCode":"C18106","definition":"A protein located on the cell surface, or in the cytoplasm, that binds to a specific signaling factor, such as a hormone, antigen, or neurotransmitter, causing a conformational and functional change in the receptor molecule.  The ligand-bound receptor then alters its interaction with target molecules, which leads to changes in cellular physiology through modification of the activity of one or more signal transduction pathways.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"770BE56A-1AE7-311E-E040-BB89AD431927","latestVersionIndicator":"Yes","beginDate":"2009-10-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-29","modifiedBy":"ONEDATA","dateModified":"2009-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F8B670-A87F-19B5-E040-BB89AD431EE7","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"COOPERM","dateModified":"2012-10-29","changeDescription":"v2.0 VD has increased max length from 15 to 30. Added concept annotation to VM per request by TCGA. mc 10/29/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2180933","version":"1","longName":"FNL Research Activities","context":"CIP","ClassificationSchemeItems":[{"publicId":"6788757","version":"1","longName":"QIN Breast Study","context":"CIP"}]},{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964891","version":"1","longName":"2020r1: Breast Cancer Pre-HSCT Data","context":"NHLBI"}]},{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"2842777","version":"1","longName":"Labs","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"10000685","version":"1","longName":"General","context":"NHLBI"}]},{"publicId":"2956164","version":"1","longName":"Transcend","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2956165","version":"1","longName":"Transcend CDEs","context":"NCIP"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787500","version":"1","longName":"BRCA","context":"NCIP"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280818","version":"1","longName":"UWI2014-03-01","context":"DCP"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"breast_carcinoma_progesterone_receptor_status","type":"TCGA_XML_Name","context":"NCIP"},{"name":"NHLBI","type":"USED_BY","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:value","type":"HCT_BRIDG","context":"NHLBI"},{"name":"2534236v1.0:2957355v2.0","type":"USED_BY","context":"Alliance"},{"name":"DCP","type":"USED_BY","context":"DCP"},{"name":"2534236v1.0:2957355v2.0","type":"USED_BY","context":"CCTG"},{"name":"PR status","type":"QIN Breast Study","context":"CIP"},{"name":"CIP","type":"USED_BY","context":"CIP"}],"ReferenceDocuments":[{"name":"Progesterone Receptor status","type":"Preferred Question Text","description":"Progesterone Receptor status","url":null,"context":"NCIP"},{"name":"Progesterone Receptor Status by IHC","type":"Alternate Question Text","description":"Progesterone Receptor Status by IHC\r\n\r\n","url":null,"context":"NCIP"},{"name":"Specify progesterone receptor assay results:","type":"Alternate Question Text","description":"Specify progesterone receptor assay results:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2957357","type":"BRIDG Mapping Path","description":"PerformedClinicalInterpretation.value(ANY => CD) WHERE PerformedObservation > DefinedObservation.nameCode = \"Evaluate Progesterone Receptor Status\"","url":null,"context":"NHLBI"},{"name":"DCP Question Text","type":"Alternate Question Text","description":"PR% Range","url":null,"context":"DCP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"PR status","url":null,"context":"Alliance"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"87F8B670-A964-19B5-E040-BB89AD431EE7","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"MORENOC","dateModified":"2019-12-12","changeDescription":"v2.0 CDE includes new version of VD with extended maximum length.  Curated for The Cancer Genome Atlas (TCGA) by request of T. Lichtenberg 6/2010","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}